Core Insights - Alkermes reported quarterly earnings of $0.13 per share, missing the Zacks Consensus Estimate of $0.28 per share, and down from $0.44 per share a year ago, representing an earnings surprise of -53.57% [1] - The company posted revenues of $306.51 million for the quarter, missing the Zacks Consensus Estimate by 3.22%, and down from $350.37 million year-over-year [2] - Alkermes has surpassed consensus EPS estimates only once in the last four quarters, while it has topped revenue estimates two times in the same period [2] Earnings Outlook - The sustainability of Alkermes' stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3] - The current consensus EPS estimate for the upcoming quarter is $0.46 on revenues of $346.92 million, and for the current fiscal year, it is $1.76 on revenues of $1.39 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 32% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Alkermes' stock performance [5]

Arvinas, Inc. (ARVN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of a loss of $0.86 per share. This compares to loss of $0.97 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 232.56%. A quarter ago, it was expected that this company would post a loss of $1.07 per share when it actually produced a loss of $0.63, delivering a surprise of 41.12%.Over the last four quarters, the company ...

Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -62.50%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.10 per share when it actually produced earnings of $0.09, delivering a surprise of -10%.Over the last four quarters ...

Core Insights - Biogen Inc. reported quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share, and down from $3.67 per share a year ago, representing an earnings surprise of -7.36% [1] - The company posted revenues of $2.43 billion for the quarter, exceeding the Zacks Consensus Estimate by 8.91%, and up from $2.29 billion year-over-year [2] - Biogen shares have declined approximately 20.8% since the beginning of the year, compared to a decline of -5.3% for the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $4.10 on revenues of $2.33 billion, and for the current fiscal year, it is $15.63 on revenues of $9.17 billion [7] - The estimate revisions trend for Biogen is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Puma Biotech, is expected to report quarterly earnings of $0.02 per share, reflecting a year-over-year change of +140%, with revenues anticipated at $43.96 million, up 0.4% from the previous year [9][10]

Moderna (MRNA) came out with a quarterly loss of $2.52 per share versus the Zacks Consensus Estimate of a loss of $2.92. This compares to loss of $3.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.70%. A quarter ago, it was expected that this biotechnology company would post a loss of $2.69 per share when it actually produced a loss of $2.50, delivering a surprise of 7.06%.Over the last four quarters, the company has sur ...

Company Performance - Humacyte, Inc. (HUMA) ended the latest trading session at $1.45, reflecting a +1.4% adjustment from the previous day's close, outperforming the S&P 500 which gained 0.15% [1] - The stock has decreased by 4.03% over the past month, which is worse than the Medical sector's loss of 4.39% and the S&P 500's loss of 0.21% [1] Earnings Forecast - Humacyte, Inc. is projected to report earnings of -$0.19 per share in the upcoming release, indicating a year-over-year growth of 34.48% [2] Analyst Revisions - Recent revisions to analyst forecasts for Humacyte, Inc. are important as they reflect changes in short-term business dynamics, with positive revisions indicating analysts' confidence in the company's performance [3] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a strong track record, with 1 stocks averaging an annual return of +25% since 1988 [5] - Over the last 30 days, the Zacks Consensus EPS estimate for Humacyte, Inc. has increased by 14.6%, and the company currently holds a Zacks Rank of 2 (Buy) [5] Industry Context - Humacyte, Inc. operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 78, placing it in the top 32% of over 250 industries [6] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [6]

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $509.47, moving +1.19% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.15%. Meanwhile, the Dow gained 0.35%, and the Nasdaq, a tech-heavy index, lost 0.09%.Heading into today, shares of the drugmaker had gained 3.87% over the past month, outpacing the Medical sector's loss of 4.39% and the S&P 500's loss of 0.21% in that time.The upcoming earnings release of Vertex Pharmaceuticals wi ...

Core Insights - MiMedx reported quarterly earnings of $0.06 per share, matching the Zacks Consensus Estimate, but down from $0.07 per share a year ago [1] - The company generated revenues of $88.21 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.56% and up from $84.71 million year-over-year [2] - MiMedx shares have declined approximately 28.1% year-to-date, contrasting with the S&P 500's decline of 5.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.07 on revenues of $93.5 million, and for the current fiscal year, it is $0.29 on revenues of $375 million [7] - The estimate revisions trend for MiMedx is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which MiMedx belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Alnylam Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.56 per share, reflecting a significant year-over-year decline of 250% [9]

Group 1: Company Overview - Cidara Therapeutics (CDTX) currently has a Momentum Style Score of B, indicating a positive momentum outlook [2] - The company has a Zacks Rank of 2 (Buy), suggesting strong potential for outperformance in the market [3] Group 2: Performance Metrics - CDTX shares have increased by 10.8% over the past week, outperforming the Zacks Medical - Biomedical and Genetics industry, which rose by 6.19% [5] - Over the past month, CDTX's price change is 11.63%, compared to the industry's 2.23% [5] - In the last quarter, CDTX shares increased by 5.39%, and over the past year, they have gained 76.29%, while the S&P 500 has moved -7.64% and 10.16% respectively [6] Group 3: Trading Volume - The average 20-day trading volume for CDTX is 162,652 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 4: Earnings Outlook - In the past two months, one earnings estimate for CDTX has moved higher, while none have moved lower, resulting in an increase in the consensus estimate from -$14.39 to -$7.12 [9] - For the next fiscal year, one estimate has also moved upwards with no downward revisions during the same period [9] Group 5: Conclusion - Considering all performance metrics and earnings outlook, CDTX is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a potential candidate for near-term investment [11]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Has Roche Holding AG (RHHBY) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Roche Holding AG is one of 1000 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different g ...